Resources

2 Resources for

penn bioinvestor

Subscribe to this listing via:
RSS
Email

BNET Resources

Somaxon Pharmaceuticals: FDA Close to a Decision for Silenor: The FDA will complete its review and provide an action letter to Somaxon Pharmaceuticals SOMX relating to the Silenor NDA by December 4, 2009.Insomnia has become an issue of great concern in the United States,...; Tags: Biotech, Penn Bioinvestor, Somaxon Pharmaceuticals Inc.; External links 2009-12-01
Vanda Pharmaceuticals: Heavily Undervalued: Vanda Pharmaceuticals VNDA is making a stunning come back this year as FDA finally approved its schizophrenia drug Fanapt. But the story is far from over, and there is every reason to believe VNDA is still heavily undervalued and has huge upside potential. This is a potential giant market for...; Tags: Biotech, Penn Bioinvestor, Vanda Pharmaceuticals Inc.; External links 2009-07-08

<< Previous
page 1 of 1
Next >>

Click Here

Click Here

Your Work Five Ways to Speak Like Obama

Five Ways to Speak Like Obama

Barack Obama is a master at grabbing and keeping his audience's attention, which is the number one goal of any public speaker. How does he do it? Here are five key lessons from Obama's rhetorical playbook.
Your Industry Debt Crisis Could Leave U.A.E. Too Broke to Buy Guns

Debt Crisis Could Leave U.A.E. Too Broke to Buy Guns

The U.A.E. recently announced that a major investment firm is having debt issues. This has caused a fall in world stock markets and concern that the market for defense deals will not be as good as it was once thought. Many companies were looking to the Middle East to make up for domestic market problems.
Your Money 29 Fees We Hate Most

29 Fees We Hate Most

An increasing number of businesses, from hotels to cell phone providers, are advertising bargain prices and then tacking on hidden fees and charges to boost the final cost. Here’s how you can fight back.